anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND Antineutrophil cytoplasmic antibody-associated vasculitis is characterized by small-vessel inflammation and ANCA-positive serology that often lead to end-stage kidney disease. This study investigated the outcomes of renal transplantation in patients with antineutrophil cytoplasmic antibody-associated vasculitis. MATERIAL AND METHODS A comprehensive search of PubMed, Scopus, and Embase databases was done to retrieve studies that reported on the outcomes of renal transplantation in these patients. Data on mortality, survival, infection, and relapse rates were analyzed. The quality of the included studies was evaluated using the Newcastle-Ottawa Scale for cohort studies. RESULTS Twenty-three retrospective cohort studies were included in this review. Antineutrophil cytoplasmic antibody-associated vasculitis was associated with high post-transplantation mortality rates, with a pooled rate ratio of 11.99 per 100 patient-years, but relatively favorable survival rate (hazard rate of 0.80). After renal transplantation, these patients had elevated infection rates (pooled rate ratio of 52.70 per 100 patient-years), and high risk of relapse (pooled rate ratio of 6.96), emphasizing the importance of vigilant post-transplantation monitoring. CONCLUSIONS End-stage kidney disease patients with vasculitis, undergoing renal transplantation, are at elevated risk of mortality and postoperative infection compared to patients without antineutrophil cytoplasmic antibody-associated vasculitis. The risk of relapse is also high in these patients. However, renal transplantation offers a survival advantage for vasculitis patients who survive the early post-transplantation period.
PURPOSE: The benefits of statins for ischemic cardio-cerebrovascular diseases are well known. However, concerns around muscle adverse events still exist. We therefore aimed to compare the muscle safety of individual statins in adults.
METHODS: PubMed, Embase, Cochrane Central Register of Controlled Trials and Web of Science were searched to include double-blind randomized controlled trials (RCTs) comparing one statin with another or with control treatment. Pairwise meta-analyses and network meta-analyses were undertaken with Stata 14.0 software. Relative risk (RR) with 95% confidence intervals (CIs) was adopted for each outcome.
RESULTS: A total of 83 RCTs were included. In the pairwise meta-analysis, statins were significantly associated with only a slight increase in muscle symptoms compared with control (RR=1.05; 95% CI=1.01-1.09). In the drug-level network meta-analyses, no statistically significant difference was found between individual statins in the incidence of muscle symptoms, myalgia, myopathy, rhabdomyolysis, creatine kinase (CK) >10 times the upper limit of normal (ULN) or discontinuation due to muscle adverse events. In the dose-level network meta-analyses, there were no statistically significant dose-dependent effects on any outcomes except that moderate-intensity statins had a higher incidence of muscle symptoms than control (RR=1.13; 95% CI=1.01-1.27). Moderate simvastatin (RR=6.57; 95% CI=1.26-34.41) and moderate pravastatin (RR=5.96; 95% CI=1.00-35.44) had a statistically significantly higher incidence of CK >10×ULN compared with moderate atorvastatin. Lipophilic statins and statins metabolized by liver cytochrome P450 3A4 were not associated with an increased risk of muscle adverse events.
CONCLUSION: Statins may be generally safe on muscle. Moderate atorvastatin may be superior to equivalent simvastatin and pravastatin in muscle tolerability.
542,316. Vitamins. LEDERLE LABORATORIES, Inc. May 1, 1940, No. 7848. Convention date, May 11, 1939. [Class 2 (iii)] [Also in Group VI] A vitamin-containing liver extract is prepared by extracting finely-ground mammalian liver with acidified water at pH 5.4 at 80‹ C., concentrating the extract to a thick syrup and either adding 95 per cent. alcohol and extracting the precipitate with hot 80 per cent. alcohol or extracting the thick syrup with hot 80 per cent. alcohol; the extract is concentrated to a thin syrup, distilled water and hydrochloric acid being added to make an N/10 solution; the active substances are adsorbed on Fuller's earth and eluted with a mixture of dioxane, methyl alcohol, acetone and distilled water, and the final solution is concentrated until each c.c. corresponds with 100-200 grams of liver. To make a solution suitable for parenteral injection, and containing all the ingredients of the vitamin B complex, the liver extract concentrate made as described above is dissolved together with thiamin and nicotinic acid in sterile water. If desired 0.5 per cent. of alcohol may be added. The Specification as open to inspection under Sect. 91 states that the solution for injection may be made by dissolving the requisite quantities of thiamin, nicotinic acid, flavin concentrate, and vitamin B6 and filtrate factor concentrate, adding phenol and sterilizing. It is stated that additional quantities of vitamin B6 and filtrate factor are obtainable from the supernatant 95 per cent. alcoholic solution remaining after the separation of the precipitate as described above, by evaporating under vacuum, adding distilled water, filtering if necessary, adding active carbon and eluting the adsorbate with saturated aqueous amyl alcohol and then with 50 per cent. ethyl alcohol, the solutions being concentrated until each c.c. corresponds with 150-200 grams of liver. This subject-matter does not appear in the Specification as accepted.
Study 1. Everolimus 10 mg orally daily for 4 week cycle. Repeat until progression, unacceptable toxicity, refusal, or alternative therapy at any time.
The first phase of the study will follow a double-blind, placebo-controlled design. Participants randomized to the experimental group will receive intranasal oxytocin in doses of 24 IU, two times daily, for a total of 48 IU. Doses may be reduced by 8 IU/day if safety concerns emerge. During the second phase of the study, all participants will receive oxytocin, in identical doses.
Introduction: Gastric atrophy and intestinal metaplasia are the principal precursors for gastric cancer and, therefore, are considered gastric premalignant conditions. Although current guidelines recommend surveillance of individuals with these conditions, the best method for its identification and staging (histological vs endoscopy) and the best time schedule for follow-up are still controversial. Aims: To describe for the first-time patients with premalignant conditions both clinically (familial history), histologically (OLGA/OLGIM; complete/incomplete metaplasia) and endoscopically (EGGIM) using validated scales and to describe evolution of these parameters through time. To estimate prospectively the gastric cancer risk according to EGGIM stages. To define the best endoscopic surveillance follow-up for the several stages considering clinical, histological and endoscopic factors.

Methods: Multicenter study involving different gastroenterology departments from several countries. Consecutive patients older than 45 years scheduled for upper endoscopy in each of these centers will be evaluated by High-Resolution-endoscopy with virtual chromoendoscopy and EGGIM will be calculated. Guided biopsies (if areas suspicious of IM) and/or random biopsies (if no areas suspicious of IM) in antrum and corpus will be made and OLGA/OLGIM stages calculated. Patients will be evaluated in clinical consultation and database will be fulfilled. All patients will be eradicated for Helicobacter pylori infection if positive. At that occasion, all the patients with EGGIM\>5 and/or OLGA III/IV and/or OLGIM III/IV will be randomized for yearly (12 to 16 months) or every three years (32-40 months) endoscopic follow-up during a period of 6 years (SUPREME I). Endoscopic observational follow-up will be scheduled for patients with EGGIM 1-4 and OLGIM I/II at 3 and 6 years (SUPREME II). For individuals with no evidence of IM (EGGIM 0 and OLGIM 0, OLGA 0-II) a follow-up endoscopy 6 years after will be proposed (SUPREME III).
A system and method for generating a dosing aid label for a syringe are described. In a method, patient information and medicament information are received. The medicament information includes one or more of a description of the medicament, a recommended dosage of the medicament and concentration information relating to the medicament. A dosing aid associated with the patient information and medicament information is generated. The dosing aid includes dosing information which is usable in guiding administration of a dose of the medicament. A print instruction message is transmitted to a printing device. The instruction message is configured to instruct the printing device to print a dosing aid label including the dosing aid on the syringe or a sheet of material configured to be affixed to a syringe. The dosing aid label is usable in guiding administration of the dose of the medicament to the patient.
The aromatase inhibitors are drugs already approved for the treatment of breast cancer in the adjuvant and metastatic setting, and have demonstrated a superiority when compared to other hormone therapy agents as tamoxifen. FRAGRANCE is a trial of neoadjuvant hormone therapy activated in September 2004 at the Jules Bordet Institute. The main objective of this study is to find a genetic signature of de novo resistance to letrozole The standard dose of letrozol, 2,5 mg/day, is given orally during 4 months previous to the definitive breast surgery. The advantages of the neoadjuvant setting are a) the possibility to directly evaluate the response to therapy, which is of great value to decide adjuvant treatment; b) the increase chance of performing breast conserving surgery; c) and, because a tumor sample is obtained before and after treatment, the identification of predictive markers of response or resistance to treatment, including a genetic signature, obtained using the microarray technology. Eligible patients are women with early hormonal receptor positive breast cancer, with any contra-indication or refusal to the administration of chemotherapy The side effects of letrozole are already well known, and include more commonly hot flashes, nausea and vomiting, headache, arthralgia/myalgia, fatigue, and oedema. After surgery, adjuvant treatment will be done according to the standard practice of the Institute, considering the possibility of continuing letrozole for a total of at least 5 years, if a satisfactory response is achieved The first part of this trial will include 49 patients.

This trial will soon become a multicenter, multinational trial of 160 patients.
The aim of this study is to assess the acceptability and effectiveness of a six-session, modular, repeating group for low-income women who have symptoms of depression and/or post-traumatic stress disorder (PTSD) following interpersonal trauma exposure. Group participants will be recruited from public sector/safety net primary care clinics. Study participants will be randomized to immediate or delayed treatment. Participants in both conditions will receive information about PTSD and depression, in the form of a brochures and a DVD about trauma and its emotional consequences. Groups will be comprised of three components at each meeting: psycho-education, current relationship issues, and coping skills. Each group session will focus on a different aspect of education. Next, relationship difficulties typically associated with the symptoms discussed in that module will be addressed, and there will be group discussion about participants' relationship difficulties. Each group will end with the therapist teaching a coping skill that fits with the issues discussed earlier. Participants will be free to attend any of the sessions they missed during the first group when the group repeats. Participants in the delayed condition will be able to attend the groups after a 12-week waiting period. Assessments of PTSD, depression, functioning, and quality of life will be conducted at three time points: baseline (prior to the start of the group), 12 weeks after the start of the group, and 6 months from the start of the group. Gift cards will be sent to the women for completing each of the assessments.
Participants who are being discharged from the regional back pain pathway who are allocated 'the Back Book'. They are followed up 6 months and 1 year. This is the control group.
This invention relates to the use of the  Amycolatopsis  sp. RC21 strain, of a mutant strain or of an active compound for inhibiting the growth of the causal agent of tuberculosis, and/or inhibiting the proliferation of cancer cells and/or for an antioxidant effect. Likewise, the subject matter of the present invention is a novel actinomycete strain of endophytic nature,  Amycolatopsis  sp. RC21, characterized by a 16S rDNA sequence SEQ No. 1 deposited in the Pubmed/NCBI nucleotide database, or a mutant strain thereof, and also a method for selecting this strain. The invention is also directed towards a method for extracting and purifying active compounds from the  Amycolatopsis  sp. RC21 strain or from a mutant strain, and also the active compounds obtained.
The invention discloses a layered facial mask. The layered facial mask contains a two-layer structure and a three-layer structure. The two-layer structure comprises a facial mask inner layer and a facial mask outer layer. The three-layer structure comprises a facial mask inner layer, a facial mask middle layer and a facial mask outer layer. The facial inner layers contain active component layers respectively. The facial middle layer is a storage layer. The facial mask outer layers are water supplementing protection layers. In the two-layer facial mask, because active components concentrate in the facial mask inner layer close to skin, the diffusion distance of the active components of the facial mask to a face is shortened, the transdermal absorption ratio in unit time is raised, and residual of the active components is reduced. Because the three-layer facial mask contains the active component storage layer, the active components release slowly, and thus the facial mask can be used for multiple times. The azone content is controlled, and the facial mask is beautiful. The hydrolyzed collagen content is adjusted, and facial mask molding is easy and the toughness is proper. The matrix part of the facial mask outer layer has a water supplementing function. Because the different layers of the facial mask employs the same matrix, the facial mask is milky or transparent and has uniformity.
Sociodemographic information form, numerical pain scale and kinesiophobia scale were applied to the patients in the experimental group after liver transplantation. They were shown 15 minutes progressive relaxation exercises prepared by Mark Connelly and Jennifer Bickel on Youtube, and then the numerical pain scale and kinesiophobia scale were applied again.
Uniparental disomy (UPD) is a rare type of chromosomal aberration that may hinder the analysis of kinship during forensic identification. Here, we investigated these genetic findings to avoid false exclusions during parentage testing. Thirty-nine fluorescently labeled, autosomal short tandem repeats (STR) were amplified in three cases, to detect parent-child relationships. Twenty-three fluorescently labeled Y-chromosome STRs were also employed. These were subjected to capillary electrophoresis. The parentage index was calculated by the bipartite or tripartite model. Single nucleotide polymorphism (SNP) microarrays were performed to further investigate the genetic mechanisms. The conclusions supported the biological mother-child relationship in three cases. However, in all cases, the alleged father and child had three autosomal STR markers, constrained to a single chromosome, which did not conform to Mendelian inheritance rules. The genotyping of 23 Y-chromosome STRs did not reveal any violations of Mendelian law. The combination of STR profiling and SNP microarrays suggested that two children had maternal UPD of chromosome 7, whilst one had UPD of chromosome 2. After excluding the three incompatible loci, the conclusions supported the biological father-child relationship in all cases. The same results were obtained when parentage testing of trios was used. Uniparental disomy may complicate the judgment of kinship in parentage testing. The possibility of UPD should be considered when incompatible STR loci are found on the same chromosome. Genetic evidence obtained through additional molecular techniques can provide better interpretation of kinship in the presence of UPD and avoid false exclusions of biological relationships.
LM-302 Dose Escalation. 6 dose levels were pre-defined, and the initial accelerated titration followed by the i3+3 design was adopted during phase I.
All participants will receive ataluren suspension orally three times a day (TID), 20 mg/kg at morning, 20 mg/kg at midday, and 40 mg/kg at evening (total daily dose 80 mg/kg) for up to 96 weeks in this study. Any participant who was receiving a reduced dose of ataluren at the end of treatment visit in study PTC124-GD-007-DMD, will be initiated ataluren therapy in this extension study at the 5-, 5-, and 10-mg/kg dose level; dose will be increased to 10, 10, and 20 mg/kg at Week 6 and to 20, 20, and 40 mg/kg at Week 12, if the preceding dose level is well tolerated.
Psoriatic arthritis patients. (CASPAR Criteria) \>18 years Imaging studies: CT and X-ray/MRI/US Physical examination by the rheumatologist and laboratory tests which are conventionally necessary for the diagnosis.
Ocular neovascularization is a hallmark of several sight-threatening diseases, including diabetic retinopathy and age-related macular degeneration. Currently, available treatments are limited and often associated with side effects. Therefore, a novel approach to ocular neovascularization treatment through utilization of polymersomes from self-assembled sphingosine-grafted hyaluronic acid (HA-Sph) amphiphilic polymers is presented. The polymersomes are generated in spherical morphologies and sizes between 97.95 - 161.9 nm with homogenous size distributions. Experiments reveal that HA-Sph polymersomes, with concentrations ≥150 µg mL-1, significantly inhibit the proliferation of human umbilical vein endothelial cells (HUVECs), while concurrently promoting the proliferation of retinal pigment epithelial cells. The polymersomes demonstrate gradual disintegration in vitro, leading to sustained release of sphingosine, which prolongs the inhibition of HUVEC proliferation (from 87.5% at 24 h to 35.2% viability at 96 h). The efficacy of polymersomes in inhibiting angiogenesis is confirmed through tube formation assay, revealing a substantial reduction in tube length compared to the control group. The findings also validate the ocular penetration capability of polymersomes through ex vivo whole porcine eye ocular penetration study, indicating their suitability for topical administration. Potentially, HA-Sph polymersomes can be harnessed to develop intricate drug delivery systems that protect the retina and effectively treat ocular diseases.
A 2D and 3D image of the participants' face will be taken. It will at least last 2-3 sec.
Obesity is a constantly growing health problem which reduces quality of life and life expectancy. Bariatric surgery (BS) for obesity is considered when all other conservative treatment modalities have failed. Comparison of the multidisciplinary programs with BS regarding to the weight loss showed that substantial and durable weight reduction have been achieved only with bariatric surgical treatments. Although laparoscopic sleeve gastrectomy is the most popular BS, it has high long-term failure rates, and it is claimed that one of every three patients will undergo another bariatric procedure within a 10-year period. Although BS provides weight loss and improvement of metabolic comorbidities, in long-term follow-up, weight gain is observed in half of the patients, while decrease in bone mass and nutritional deficiencies occur in up to 90%. Moreover, despite significant weight loss, several psychological aspects of patients are worsened in comparison to preoperative levels. Nearly one-fifth of postoperative patients with "Loss-of-eating control" meet food addiction criteria. Therefore, the benefits of weight loss following bariatric procedures alone are still debated in terms of the proinflammatory and metabolic profile of obesity.
INTRODUCTION: Tailored prophylaxis is the current treatment regimen for patients with severe haemophilia A. Recently, published guidelines describe two possible approaches, based on clinical characteristics or estimation of pharmacokinetic parameters. However, both have strengths and weaknesses, and their characteristics need to be integrated to optimize treatment appropriately. In this paper, we present a model that considers together the characteristics of prophylaxis and the relevance of each.
METHODS: The age at initiation of prophylaxis, number of bleeding events, treatment regimen, therapeutic adherence, FVIII trough levels, and joint status were analyzed in 59 patients followed at La Paz University Hospital between January 2000 and December 2019.
RESULTS: The mean duration of primary prophylaxis of 113.37 ± 57.79 months. Eighty-three percent (n = 49) had no joint status involvement at the end of follow-up (HJHS and HEAD-US = 0). The median ABR was 0.7 (IQR 0.2 -1.0) and 54.2% presented trough levels of FVIII during follow-up >1 IU/dL. 72,9% engaged in some type of physical activity and overall adherence was over 85% in all patients evaluated. The regression analysis performed, considering all these factors, showed that the initiation of prophylaxis before 21 months of age was the most relevant protective factor against the appearance of joint involvement (OR 88.33 p.031 CI 95% 1.49-5224.40) CONCLUSION: Early initiation of prophylaxis was the most relevant factor in the protection of joint status. More comprehensive analysis models adapted to the characteristics of each population, are needed to adequately individualize treatment.
PROBLEM TO BE SOLVED: To provide a blood preparation not contg. viruses. SOLUTION: A freeze dried sample of a biologically active protein compsn. which puts the protein compsn. into the state of substantially not contg. the viruses and has a prescribed moisture content is prepd. The min. or threshold moisture content which will lead to a decrease of at least 3.2log10 in virus titre when the compsn. is heated up to low-temp. sterilization conditions is determined and thereafter, the sample is heated under the low-temp. sterilization conditions under which the decrease of at least 3.2log10 will be resulted while the biological activity of the protein is maintained.
In a water heating system, vapor in the products of combustion gases is condensed in a secondary heat exchanger positioned in a housing with the primary heat exchanger and combustion chamber. The two heat exchangers are coaxial coils with the secondary coil surrounding the primary. Gases flow radially through the primary coil, axially along a baffle and then axially through the secondary coil at an increased velocity. The gas/air mixture is burned in a burner within the primary heat exchanger and the gas product are drawn through the exchangers by a blower. A water storage tank is designed to enhance stratification of hot water over cooler water. The cooler water is used to condense vapor in the secondary heat exchanger.
The invention relates to cosmetic preparations containing, each time with regard to the total weight of the preparation: a) water in a concentration ranging from 10 to 90 wt. %; b) one or more fatty acids and/or salts thereof in a concentration ranging from 5 to 50 wt. %; c) one or more emulsifiers in a concentration ranging from 0.1 to 10 wt. %; d) one or more complexing agents in a concentration ranging from 0.1 to 10 wt. %; e) one or more waxes in a concentration ranging from 0.1 to 10 wt. %, and; f) talcum powder having a mean particle size less than or equal to 5 µm and in a quantity ranging from 0.1 to 10 wt. %. The inventive preparations also optionally contain additional cosmetic and/or dermatological active substances, auxiliary substances and additives.